MedPath

CanGaroo® Registry Study

Completed
Conditions
Arrhythmias, Cardiac
Registration Number
NCT04846127
Lead Sponsor
Elutia Inc.
Brief Summary

A Multi-Center Registry Evaluating Participants Who Receive CanGaroo Envelope or No Envelope During their CIED Implantation

Detailed Description

This prospective, multi-center study will enroll up to 500 participants who are undergoing their initial CIED implant with either a CanGaroo envelope or no envelope.

Once a participant is enrolled in one of the two cohorts, each participant will have their medical history data reviewed and data will be recorded in the CRF including baseline demographics, medications, and diagnoses.

The details of the CIED procedure including any complications/AEs that occur during the procedure will be captured on the appropriate CRF.

Information collected at the follow-up visits will include documentation of post-procedure status, including any complications, adverse events, or revision/reoperation procedures that occur during the follow-up period. This information will also be collected for any unscheduled follow-ups, visits, or care encounters that occur up to 3 months post-procedure. For participants that agree and qualify for optional long-term follow-up, the same information will be collected at additional follow-up points every six months for up to five years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
500
Inclusion Criteria
  1. Participants for whom this is their first CIED implantation at a particular anatomical site.

    Participants with a history of prior CIED implants at other anatomical sites than the current site can be included, provided that the planned implant location for the current CIED procedure is the first implant procedure at that site.

  2. Participants aged 18 years or older at time of enrollment.

  3. Participant is able and agrees to provide written informed consent and use of PHI.

Exclusion Criteria
  1. Participants who have had one or more prior CIED procedures (implantations or revisions) at the current device implant site.
  2. Participants under the age of 18 at time of enrollment.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Association between participant characteristics and outcomes3 months post-procedure

Cohort comparison of clinically significant factors such as physical and demographic characteristics, medical history risk factors related to post-procedure events, and associations with outcomes and events.

Association between CanGaroo envelope use and CIED implant-related outcomes and events.3 months post-procedure

Cohort comparison of clinically significant events such as infection, wound healing issues, CIED migration, CIED erosion, or a revision/reoperation procedure.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (23)

Arkansas Heart Hospital

🇺🇸

Little Rock, Arkansas, United States

Daytona Heart Group

🇺🇸

Daytona Beach, Florida, United States

The Arrhythmia Center of South Florida

🇺🇸

Delray Beach, Florida, United States

Florida Heart Rhythm Specialists, PLLC

🇺🇸

Fort Lauderdale, Florida, United States

VA Medical Center

🇺🇸

Gainesville, Florida, United States

Cardiovascular Associates/Osceola Regional Medical Center

🇺🇸

Kissimmee, Florida, United States

Advent Health

🇺🇸

Tampa, Florida, United States

Baptist Health Floyd

🇺🇸

New Albany, Indiana, United States

St. Joseph Hospital

🇺🇸

Lexington, Kentucky, United States

Eastern Maine Medical Center

🇺🇸

Bangor, Maine, United States

Scroll for more (13 remaining)
Arkansas Heart Hospital
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.